316 related articles for article (PubMed ID: 32678032)
1. Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
Bellat V; Verchère A; Ashe SA; Law B
BMC Cancer; 2020 Jul; 20(1):661. PubMed ID: 32678032
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor.
Wu YS; Quan Y; Zhang DX; Liu DW; Zhang XZ
Biol Pharm Bull; 2017; 40(10):1747-1753. PubMed ID: 28966246
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
6. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.
Wu Y; Zhang D; Wu B; Quan Y; Liu D; Li Y; Zhang X
Chem Pharm Bull (Tokyo); 2017 Aug; 65(8):768-775. PubMed ID: 28539531
[TBL] [Abstract][Full Text] [Related]
8. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
9. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells.
Niwa AM; D Epiro GF; Marques LA; Semprebon SC; Sartori D; Ribeiro LR; Mantovani MS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):557-71. PubMed ID: 26932586
[TBL] [Abstract][Full Text] [Related]
11. A novel resveratrol-salinomycin combination sensitizes ER-positive breast cancer cells to apoptosis.
Venkatadri R; Iyer AKV; Kaushik V; Azad N
Pharmacol Rep; 2017 Aug; 69(4):788-797. PubMed ID: 28605700
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
13. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
Corrales-Sánchez V; Noblejas-López MDM; Nieto-Jiménez C; Pérez-Peña J; Montero JC; Burgos M; Galán-Moya EM; Pandiella A; Ocaña A
J Cell Mol Med; 2020 Mar; 24(5):3117-3127. PubMed ID: 32032474
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
[TBL] [Abstract][Full Text] [Related]
16. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.
Koo KH; Kim H; Bae YK; Kim K; Park BK; Lee CH; Kim YN
Cell Death Dis; 2013 Jun; 4(6):e693. PubMed ID: 23807222
[TBL] [Abstract][Full Text] [Related]
17. Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells.
Dewangan J; Tandon D; Srivastava S; Verma AK; Yapuri A; Rath SK
Apoptosis; 2017 Oct; 22(10):1246-1259. PubMed ID: 28748373
[TBL] [Abstract][Full Text] [Related]
18. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
